Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
I-TECH: Ivermectin in High Risk COVID-19
NCT04920942Phase 3Completed
- Sponsor
- Clinical Research Malaysia
- Start
- May 2021
- Primary completion
- Oct 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of ivermectin in coronavirus disease 2019 (COVID-19) (2 arms), sponsored by Clinical Research Malaysia. Primary endpoints: Number of Patients who Progressed to Severe Disease (Clinical stage 4 or 5) at 28 days and Time Required for Patients on Treatment Arm to Progressed to Severe Disease at 28 days. Started May 2021; status: completed.
02
Drugs
ivermectin
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on NCT04920942.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04920942.